source
- BlossomHill and Latigo close IPO week with $496 million raisedBlossomHill Therapeutics, a cancer‑focused biotech, completed its initial public offering this week. Latigo, a company developing non‑opioid pain treatments, also went public at the same time. To…
- Latigo Biotherapeutics reports non-opioid drug cuts acute pain in Phase 2b trialLatigo Biotherapeutics announced that its experimental non-opioid analgesic demonstrated a reduction in acute pain in a Phase 2b clinical trial. The study results suggest the candidate may offer a…